{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:39:47Z","timestamp":1793147987199,"version":"4.5.0"},"reference-count":33,"publisher":"European Respiratory Society (ERS)","issue":"155","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2019,9,26]]},"published-print":{"date-parts":[[2020,3,31]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Many sarcoidosis patients experience a reduction in health-related quality of life (HRQoL) and a majority of patients report fatigue. Historically, drug trials in sarcoidosis have focused on changes in chest radiographs, lung function parameters and biomarkers, while HRQoL and fatigue have not been the main outcomes examined. We performed a systematic review of the literature to evaluate the existing evidence on the effects of pharmacological interventions on HRQoL and fatigue outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The systematic search was performed in Medline and Embase and yielded 15 records covering seven randomised controlled trials and seven single-arm open label studies, which were included in a qualitative synthesis (the results of one study were included in two publications). 12 studies evaluated immunosuppressive and\/or immunomodulatory therapies and two studies evaluated stimulants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine out of the 14 studies observed positive treatment effects from the interventions on HRQoL and\/or fatigue, exceeding the minimal important difference. The risk of bias was generally high with only three studies rated as having a low risk of bias. The results suggest a potential for improvement in HRQoL and\/or fatigue in patients with active disease who are either untreated or treated but not yet fully stabilised or therapy refractory.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>More randomised, double-blind and placebo-controlled trials are needed to expand the evidence base on these important outcome parameters.<\/jats:p><\/jats:sec>","DOI":"10.1183\/16000617.0057-2019","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T13:44:40Z","timestamp":1580305480000},"page":"190057","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review"],"prefix":"10.1183","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-8549","authenticated-orcid":false,"given":"Roeland","family":"Vis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1334-2144","authenticated-orcid":false,"given":"Ewoudt M.W.","family":"van de Garde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Grutters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid H.E.","family":"Korenromp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"key":"2024102403432884000_29.155.190057.1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.ats4-99"},{"key":"2024102403432884000_29.155.190057.2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2024102403432884000_29.155.190057.3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S2213-2600(15)00199-X","article-title":"New treatment strategies for pulmonary sarcoidosis: antimetabolites, biological drugs, and other treatment approaches","volume":"3","author":"Baughman","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024102403432884000_29.155.190057.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-2977(98)00058-8"},{"key":"2024102403432884000_29.155.190057.5","doi-asserted-by":"publisher","DOI":"10.1378\/chest.125.3.997"},{"key":"2024102403432884000_29.155.190057.6","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00002512"},{"key":"2024102403432884000_29.155.190057.7","first-page":"117","article-title":"Association between physical functions and quality of life in sarcoidosis","volume":"31","author":"Drent","year":"2014","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"2024102403432884000_29.155.190057.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2018.PA5219"},{"key":"2024102403432884000_29.155.190057.9","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2024102403432884000_29.155.190057.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"2024102403432884000_29.155.190057.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.177"},{"key":"2024102403432884000_29.155.190057.12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"key":"2024102403432884000_29.155.190057.13","first-page":"289","article-title":"Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial","volume":"32","author":"Baughman","year":"2016","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"2024102403432884000_29.155.190057.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-011-1844-0"},{"key":"2024102403432884000_29.155.190057.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2011.00276.x"},{"key":"2024102403432884000_29.155.190057.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.056"},{"key":"2024102403432884000_29.155.190057.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00000914"},{"key":"2024102403432884000_29.155.190057.18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00227014"},{"key":"2024102403432884000_29.155.190057.19","first-page":"124","article-title":"Fatigue and health-related quality of life in patients with pulmonary sarcoidosis treated by oral corticosteroids","volume":"33","author":"Aggarwal","year":"2016","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"2024102403432884000_29.155.190057.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-017-9994-4"},{"key":"2024102403432884000_29.155.190057.21","first-page":"51","article-title":"The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis","volume":"23","author":"Judson","year":"2006","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"2024102403432884000_29.155.190057.22","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2012.00332"},{"key":"2024102403432884000_29.155.190057.23","first-page":"201","article-title":"Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis","volume":"30","author":"Drake","year":"2013","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"2024102403432884000_29.155.190057.24","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2952"},{"key":"2024102403432884000_29.155.190057.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2012.02.016"},{"key":"2024102403432884000_29.155.190057.26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-0037-1602589","article-title":"Quality of life in sarcoidosis","volume":"38","author":"Judson","year":"2017","journal-title":"Semin Respir Crit Care Med"},{"key":"2024102403432884000_29.155.190057.27","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-013-0438-1"},{"key":"2024102403432884000_29.155.190057.28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2010.00214.x"},{"key":"2024102403432884000_29.155.190057.29","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-014-0514-0"},{"key":"2024102403432884000_29.155.190057.30","first-page":"76","article-title":"Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them","volume":"25","author":"Baughman","year":"2008","journal-title":"Sarcoidosis Vasc Diffus Lung Dis"},{"key":"2024102403432884000_29.155.190057.31","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00156314"},{"key":"2024102403432884000_29.155.190057.32","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1262216"},{"key":"2024102403432884000_29.155.190057.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0057-2019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:01:26Z","timestamp":1740373286000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0057-2019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":33,"journal-issue":{"issue":"155","published-online":{"date-parts":[[2020,1,29]]},"published-print":{"date-parts":[[2020,3,31]]}},"alternative-id":["10.1183\/16000617.0057-2019"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0057-2019","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,29]]}}}